The Renewal Trap: Why Keeping Your Legacy Vendor Is the Riskier Bet

The renewal conversation arrives on schedule. Your legacy risk and quality vendor sends the deck. The account team shows up. The numbers look familiar. And somewhere in the room, someone says: "We know how it works. Switching is risky."

That logic made sense once. It no longer does.

The healthcare payer market has shifted faster in the last two years than in the previous decade. V28 risk adjustment is forcing complete HCC recoding. CMS is overhauling Star Ratings, removing 11 administrative measures and adding new ones. The 2027 interoperability deadline is approaching. Medicare Advantage rate changes are reshaping premium math. And your competitors are not waiting to see how their legacy vendors respond.

The real risk is not switching. The real risk is staying while the market moves.

The Installed Base Is Not the Same as the Right Answer

Legacy vendors built their footprints during a different era of payer operations. Risk adjustment was largely retrospective. HEDIS reporting was a seasonal exercise. Stars improvement was managed by a quality team in one corner of the organization. These workflows were separate by design, because the data infrastructure to connect them did not exist.

That infrastructure now exists. And the plans that are winning are the ones using it.

The problem with renewing a legacy contract is not that the vendor is incompetent. Many have deep expertise in specific domains. The problem is structural: their architecture reflects the world as it was, not the world as it is. Risk adjustment runs in one system. Quality management runs in another. Outreach happens in a third. Your team spends significant time reconciling outputs across platforms that were never built to talk to each other.

Every quarter you operate that way, you are paying for the inefficiency twice: once in vendor fees, and once in the staff hours required to bridge the gaps.

V28 Is Not a Patch. It Is a Rebuild.

The transition to V28 risk adjustment is the clearest stress test for any payer technology platform. V28 does not simply adjust coefficients. It restructures the logic of HCC coding in ways that require recoding across your entire member population.

Legacy systems built around V24 logic are not well-positioned to handle this at scale. Many plans are discovering that their existing vendors can support V28 compliance in theory but cannot automate the recoding work in practice. The result is a manual burden that falls on your clinical documentation and coding teams, at exactly the moment when those teams are already stretched.

This is where modern AI agents change the equation. An HCC Coding Agent built for V28 can process retrospective charts at a scale no manual team can match. It identifies gaps, flags documentation issues, and generates coding recommendations with the specificity that RADV audit defense requires. That is not a feature upgrade. That is a fundamentally different capability.

If your current vendor cannot demonstrate V28-native automation at the chart level, you are not getting a risk adjustment solution. You are getting a compliance checklist.

Stars Is a Revenue Number, Not a Quality Report

Health plan executives sometimes treat Star Ratings as a quality metric. It is a revenue metric. A one-star improvement in Medicare Advantage translates to $500 million to $1 billion in revenue impact for large plans, drawn directly from CMS rate and quality bonus structures.

CMS is also changing what Stars measures. The removal of 11 administrative measures and the addition of Depression Screening means your current performance baseline is shifting. Plans that built their Stars strategy around the old measure set are starting 2026 with a recalibration problem.

The plans that will outperform are the ones with a platform that can identify gaps in real time, run outreach campaigns tied to specific measures, track closure rates across the full Stars lifecycle, and connect medication adherence data from pharmacy networks. That is not a description of four separate tools. That is a description of one unified system.

Innovaccer's Galaxy platform was built for exactly this. Galaxy covers the full Stars lifecycle: gap identification, member outreach, closure tracking, and performance reporting, all on a single platform. It is rated #1 Best in KLAS 2026 for Data Analytics Platforms in the payer segment, with a KLAS score of 90.5 against a market average of 87.2. That rating reflects what health plans actually experience when they use it, not what a vendor claims in a sales deck.

The question worth asking your legacy vendor is simple: can they show you a unified Stars workflow from gap identification to closure in a single system? If the answer involves multiple modules, multiple logins, or a professional services engagement to connect the pieces, you have your answer.

The Consolidation Argument Is Financial, Not Just Operational

Payer technology stacks have grown by accumulation. A risk adjustment vendor here. A HEDIS tool there. A pharmacy quality network somewhere else. Each purchase made sense at the time. The aggregate cost of running them in parallel rarely gets scrutinized until a CFO asks the right question.

The consolidation case for a unified platform is not primarily about convenience. It is about compounding returns. When your risk adjustment data and your quality data live in the same system, your teams can identify members who have both an HCC coding gap and an open HEDIS measure. They can prioritize outreach based on combined impact. They can close two gaps in one interaction instead of running two separate campaigns.

That kind of coordination is not possible when your data lives in separate systems. And it is not something a legacy vendor can retrofit through an API integration. The data needs to be unified at the foundation, not connected at the surface.

Plans using Galaxy gain access to unified claims and clinical data, automated compliance workflows, and measurable ROI through improved accuracy and reduced manual overhead. The platform connects to 400-plus pre-built EHR and data connectors and applies more than 6,000 data quality rules to ensure the underlying data is reliable before any analysis runs on top of it. That foundation matters. Insights built on incomplete or inconsistent data produce incomplete and inconsistent decisions.

For plans that also need to close pharmacy-driven quality gaps, PQS connects health plans to a network of 65,000-plus community, specialty, and health system pharmacies across all 50 states. More than 21 million care gaps have been delivered through that network, and it carries NCQA Data Aggregator Validation, the industry's recognized standard for data integrity in pharmacy quality programs. If your current Stars strategy does not include a pharmacy channel with that kind of reach, you are leaving adherence measures underperformed.

The Switching Cost Argument Deserves Scrutiny

Every legacy vendor renewal conversation eventually arrives at switching costs. Implementation risk. Data migration. Staff retraining. The implicit message is that the known friction of staying is smaller than the unknown friction of moving.

That argument deserves scrutiny. The cost of staying includes the manual work your team does today to compensate for system gaps. It includes the revenue you do not capture because your Stars performance is below where it could be. It includes the RADV audit exposure that comes from incomplete documentation. It includes the V28 recoding backlog that grows each quarter your platform cannot automate it.

Those costs are real. They are just harder to see on a renewal invoice.

The switching cost argument also assumes the gap between your current platform and a modern alternative stays constant. It does not. AI agent capabilities are advancing quickly. Plans that move now are building institutional knowledge and workflow integration that compounds over time. Plans that renew legacy contracts are deferring that compounding.

There is also a competitive dimension. Your market peers are making platform decisions right now. The plans that move first on unified risk and quality platforms will have a structural advantage in Stars performance, RADV readiness, and V28 accuracy. That advantage does not reverse easily once it is established.

What a Modern Platform Evaluation Actually Looks Like

If you are in a renewal cycle, the evaluation does not need to start with an RFP. It can start with a specific question: show me how your platform handles the V28 recoding requirement for a member population of our size, in a single workflow, without manual reconciliation across systems.

Ask the same question about Stars gap closure. Ask it about RADV audit documentation. Ask it about pharmacy adherence integration. The answers will tell you whether you are looking at a modern platform or a legacy system with a new interface.

Galaxy unifies risk adjustment and quality management on a single AI-driven foundation, automates the workflows that currently consume your team's time, and is rated by health plans, not by analysts, as the top-performing payer data analytics platform in the market.

The renewal that feels safe is not always the one that is safe. The question worth asking is not whether switching has costs. It does. The question is whether staying has costs you are not currently measuring.

If you want to see how Galaxy performs against your specific risk and quality challenges, the conversation starts at innovaccer.com/request-a-demo-in.